Elastrin Therapeutics

📍 Oxford, United Kingdom🗓 Founded 2017👥 6 employees💰 Last funded Feb 2021
Biotechnology Research🌐 elastrin.com
Website LinkedIn
Elastrin Therapeutics is a UK and US-based biotech developing novel therapies to reverse cardiovascular disease. Its underlying technology was developed by Dr. Naren Vyavahare during the last 20 years at Clemson University, in collaboration with Dr. Charles Rice. Our team built a proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries.
2
Total investors
1
Early stage
1
Mid stage
0
Late stage
2017
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Switzerland
1
Germany
1
Frequently asked questions
Who invested in Elastrin Therapeutics?
Elastrin Therapeutics has 2 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage.
When did Elastrin Therapeutics last raise funding?
The most recent investment in Elastrin Therapeutics recorded on gritt.io was in February 2021.
When was Elastrin Therapeutics founded?
Elastrin Therapeutics was founded in 2017.
What industry is Elastrin Therapeutics in?
Elastrin Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Elastrin Therapeutics based?
Elastrin Therapeutics is headquartered in Oxford, United Kingdom.